FDA accepts Roche Lunsumio+Polivy supplemental BLA; EMA CHMP backs Ocrevus ages 10+
Roche said the FDA accepted a supplemental BLA for Lunsumio with Polivy in 2L+ DLBCL based on SUNMO data. Roche also said the EMA CHMP backed Ocrevus IV for pediatric relapsing multiple sclerosis in patients age 10+ after OPERETTA 2 showed non-inferiority versus...?